PALISADE BIO, INC. (PALI)

Every figure this model derived for PALI, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2024-12-31
cash 130,172,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 127,260,000 AssetsCurrent 2026-06-30
current liabilities 5,246,000 LiabilitiesCurrent 2026-06-30
equity 121,748,000 StockholdersEquity 2026-06-30
interest expense 10,000 InterestPaidNet 2026-06-30
ocf -18,190,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 0 RevenueFromContractWithCustomerIncludingAssessedTax 2026-06-30
sbc 12,899,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up PALI on one particular measure came for.

RatioValue
current ratio24.26
current ratio reported24.26
dilution pct3840.07
interest cover-3534.9

What to be careful about

What this model itself distrusts about PALI's figures. Written by the derivation as it ran, not added afterwards.